Neurodegeneration in multiple sclerosis: novel treatment strategies - Wikidata - awgldk - TriplyDB

Neurodegeneration in multiple sclerosis: novel treatment strategies

Neurodegeneration in multiple sclerosis: novel treatment strategies

http://www.wikidata.org/entity/Q22241472

about

Cholesterol homeostasis: a key to prevent or slow down neurodegeneration Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?New and emerging immune-targeted drugs for the treatment of multiple sclerosis Role of microglia in CNS autoimmunity Current automated 3D cell detection methods are not a suitable replacement for manual stereologic cell counting Amelioration of experimental autoimmune encephalomyelitis by anatabine Thalamus pathology in multiple sclerosis: from biology to clinical application.Evaluating the Role of Corticosteroid Pulse Therapy in Patients With Secondary Progressive Multiple Sclerosis Receiving Mitoxantrone: A Double Blind Randomized Controlled Clinical Trial.Defective autophagy is associated with neuronal injury in a mouse model of multiple sclerosis Stem cell transplantation in neurological diseases: improving effectiveness in animal models Lipolysaccharide-Induced Neuroinflammation Is Associated with Alzheimer-Like Amyloidogenic Axonal Pathology and Dendritic Degeneration in Rats.Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis Granzyme B-inhibitor serpina3n induces neuroprotection in vitro and in vivo.Can vitamin d suppress endothelial cells apoptosis in multiple sclerosis patients?Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.Current and future therapies for multiple sclerosis.Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects.The benefits and detriments of macrophages/microglia in models of multiple sclerosis PET imaging in multiple sclerosis.Remyelinating strategies in multiple sclerosis.Patients characteristics influencing the longitudinal utilization of steroids in multiple sclerosis--an observational study.Dendritic cells as therapeutic targets in neuroinflammation.Characterization of the NT2-derived neuronal and astrocytic cell lines as alternative in vitro models for primary human neurons and astrocytes.Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis.Multiple sclerosis and the blood-central nervous system barrier.Probenecid arrests the progression of pronounced clinical symptoms in a mouse model of multiple sclerosis.Oligodendrocyte Lineage Cells in Chronic Demyelination of Multiple Sclerosis Optic Nerve.Comparative Neuroregenerative Effects of C-Phycocyanin and IFN-Beta in a Model of Multiple Sclerosis in Mice.Remyelination in multiple sclerosis: realizing a long-standing challenge.Neuronal expression of the transcription factor serum response factor modulates myelination in a mouse multiple sclerosis model.Comorbidity in US patients with multiple sclerosis.Simultaneous Ablation of Neuronal Neurofascin and Ankyrin G in Young and Adult Mice Reveals Age-Dependent Increase in Nodal Stability in Myelinated Axons and Differential Effects on the Lifespan.

P2860

Q21129248-07569C4C-3907-4B2C-A767-73F2782E1887 Q26799233-33872D07-0552-45C9-8900-C6CB2DF462C8 Q26997067-9D3A3FF9-937B-47E4-9A2B-6AC98A3CF86C Q27003940-6971EE68-75DE-4717-9811-BF097C0F6789 Q28364911-3156CB8F-2BCC-4CBE-A753-8CB735983246 Q28485371-7E90898F-B2A0-41BE-9BF4-4ABEAA84378F Q30871067-AE6C3E85-B8C2-4E49-9AC3-6D0EDAF22877 Q31023281-1421DED6-1199-4BAC-9240-7580501D0EDA Q33808745-341E0FEA-3BE8-48B5-B237-50CDAF54E18C Q34391064-DE1BA5A0-AC05-4979-894E-B12845A633EF Q34412996-993ED2E5-EFED-48C8-B581-2B6734C607D2 Q34769676-E50AAF50-8112-4942-BA36-C459345DB10B Q36023188-F0A6FC85-4F04-4B1E-92AE-1A2376F8BFA3 Q36917731-4E4FE7CB-21C6-4CB8-81B3-5DDAE8289CA5 Q37033692-A6DBB120-77FB-4F7E-825F-0664475B3D2C Q37287769-72BA2F9A-DED3-445A-84D6-2A50E18344D4 Q38101003-A016E6AF-A1E8-4BDC-8641-97450E39CEF7 Q38120527-7A9BCC73-4722-478B-AAED-411787F01798 Q38210272-173468E9-F10E-49C5-BD7B-2B1731D669FA Q38261543-0FC31A4F-7444-491A-9887-F4EE830A69B2 Q38415327-BE979008-3637-47CB-9A09-4F7E6F213A75 Q38771884-BB31E4A9-9D8A-4D80-B471-966DB2D6F10C Q38997993-DB7EFCDE-3954-4EE9-A822-E36FA0413E61 Q39298719-ED766AF8-F055-4A9E-BAEF-22DE5C7CA80D Q41475478-037F421E-747F-44EC-8A6F-EEC4EC1E1EE9 Q43136157-D317031E-9D05-413A-B787-F8EE638CBC02 Q47114284-CD2B5B05-CEB5-41CE-A271-820200CF56EC Q48572449-54DD99AC-0D03-4D09-847E-33E14115D789 Q50239453-A1133DFC-3E3C-4179-8B6B-5C972246373F Q53281324-925B9DE1-2988-4F3B-B06B-22B80B5429AF Q53629771-CDFA1888-4F41-43D7-AFDC-0465E626BA27 Q55098363-6EB81BFC-CBEB-44E9-9072-ADE735D70826 Q55360507-F6A9069B-7C0F-45D7-8440-4E40E9053B9C

P2860

Neurodegeneration in multiple sclerosis: novel treatment strategies

http://www.wikidata.org/entity/Q22241472

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Neurodegeneration in multiple sclerosis: novel treatment strategies

@ast

Neurodegeneration in multiple sclerosis: novel treatment strategies

@en

Neurodegeneration in multiple sclerosis: novel treatment strategies

@en-gb

Neurodegeneration in multiple sclerosis: novel treatment strategies

@nl

type

label

Neurodegeneration in multiple sclerosis: novel treatment strategies

@ast

Neurodegeneration in multiple sclerosis: novel treatment strategies

@en

Neurodegeneration in multiple sclerosis: novel treatment strategies

@en-gb

Neurodegeneration in multiple sclerosis: novel treatment strategies

@nl

prefLabel

Neurodegeneration in multiple sclerosis: novel treatment strategies

@ast

Neurodegeneration in multiple sclerosis: novel treatment strategies

@en

Neurodegeneration in multiple sclerosis: novel treatment strategies

@en-gb

Neurodegeneration in multiple sclerosis: novel treatment strategies

@nl

P1433

Q22241472-F4CADE85-CCFF-4ED2-A21E-88204BD0D89E

P1476

Q22241472-8094BA17-8839-4A39-B1B5-5696CD6613EF

P2093

Q22241472-0F7C8A22-9EBE-4173-A5AB-790411565F7D

P2860

Q22241472-019902B9-B8F3-46AE-88AB-D54622B835C5

Q22241472-0312AEBC-9C58-4E73-A086-A730D69BA03E

Q22241472-0C449D53-FF3D-40A5-A78F-F13F837E42C9

Q22241472-118F7D77-0188-4D4B-BB89-056CBE951A05

Q22241472-122B7A38-20DC-4DBC-8D4C-561720890DCB

Q22241472-12EACB91-47A8-4FBF-8434-07D8472E06FF

Q22241472-158F1F7A-713E-40B7-9560-0DBF1246E1FB

Q22241472-17CDA9B4-E617-4CBA-B8C6-3C76033197B0

Q22241472-1881D7DF-9A1C-4020-A627-D86D00FC9F82

Q22241472-19F77FC6-2959-4571-AB5A-4D201636AA0A

P304

Q22241472-4A2B265E-5911-4D31-819D-48DA5509DA5E

P31

Q22241472-CB1798DC-772F-4D55-952A-7FBC78FF4BCE

P356

Q22241472-8B336FC6-8CEC-400A-8174-265AC38CD338

P407

Q22241472-469D231C-2758-4548-8145-7E8028F4E150

P433

Q22241472-D09D541D-807B-4636-A0D0-D8E73E7D76E7

P478

Q22241472-4F3B07DB-B95B-4B29-AE7C-E36CDCC31CB2

P50

Q22241472-928FFC73-AD39-4504-AE35-21C67E76969F

Q22241472-A63CE032-1B59-4BA9-915A-F9D3DC1966EE

P577

Q22241472-5BF12346-7720-4948-A008-0AAF8F5E752B

P5875

Q22241472-92CD3615-CBDC-48B4-B1EC-B87793F7B93E

P698

Q22241472-8E8629D3-5433-48BD-83B8-F23A76760F0A

P921

Q22241472-1ED6C804-8785-4767-8895-8F1D69C73846

P356

P1433

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

P1476

Neurodegeneration in multiple sclerosis: novel treatment strategies

@en

P2093

Felix Luessi

http://www.w3.org/2001/XMLSchema#string

P2860

Defining the clinical course of multiple sclerosis: Results of an international survey

Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans.

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress

Mitochondrial defects in acute multiple sclerosis lesions

Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

P304

1061-76; quiz 1077

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERN.12.59

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232064154

http://www.w3.org/2001/XMLSchema#string

P698

23039386

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis